







Niwa et al. Figure S1 (related to Figure 1)


A

C.e. 410 L Q **E** S E K L M A E 420
 M.m. 437 L K **E** T E K I I A E 447


C.e. 608 M L E M **E** S Q Y R R 617
 M.m. 642 L Q E L E D Q Y R R 651




Niwa et al., Supplementary Figure S2 (related to Figure 2)



Niwa et al., Supplemental Figure S3



Niwa et al., Supplementary Figure S4 (related to Figure 6)



Cargo binding induces the dimerization (Klopfenstein et al. 2002)

Niwa et al. Supplementary Figure S5

1 **Supplementary Figure legends**

2 **Figure S1 (related to Figure 1)**

3 (A) The representative images of *unc-104(wy865)* (V6I) and *unc-104(wy798)* (E412K).

4 Bars, 50 μ m

5 (B) A representative Western blotting showing the expression level of SNB-1. The
6 amount of SNB-1 is not changed in *unc-104(gf)* alleles.

7

8 **Figure S2 (related to Figure 2)**

9 (A) The alignment of CC1 and CC2 mutations in *Caenorhabditis elegans* (C.e.) and
10 *Mus musculus* (M.m.).

11 (B and C) (B) Representative images of *unc-104(e1265)* and animals that were
12 rescued by KIF1A. KIF1A was expressed by the *unc-104* promoter. (C) The
13 localization of synaptic vesicles in DA9 neurons. Bars, 50 μ m.

14 (D-G) *arl-8(wy271)* is rescued by expressing *arl-8* or human ARL8B. (D-F)
15 Representative images showing (D) *arl-8(wy271)*, (E) *arl-8(wy271)* expressing *C.*
16 *elegans arl-8*, and (F) *arl-8(wy271)* expressing human ARL8B. Bars, 50 μ m.
17 *Pitr-1::arl-8* or *Pitr-1::ARL8B* were injected to *arl-8(wy271)* animals. *Podr-1::GFP* was
18 used as a co-injection marker. Bars, 50 μ m. (G) The synaptic vesicle phenotype was
19 sorted as "rescued" or "not rescued". Note that both *arl-8* and human ARL8B could
20 rescue the mislocalization of synaptic vesicles in the *arl-8* mutant.

21 (H) The localization of KIF1A(E439K)::GFP and KIF1A(G631R)::GFP in COS-7 cells.
22 Bars, 5 μ m.

23 (I) The motor domain of UNC-104 and UNC-104(V6I) were purified from E.coli using
24 metal ion affinity chromatography. The speed of microtubules in microtubule gliding
25 assays, n = 25. Mean \pm Standard deviation.

26

27 **Figure S3 (related to Figure 3)**

28 Confocal images of the localization of UNC-104 and UNC-104 mutants visualized by
29 fusing with GFP. While wt UNC-104 is diffuse, UNC-104 mutants strongly accumulate
30 to the tip of the DA9 axon and under the detectable level in the axonal shaft.

31

32 **Figure S4 (related to Figure 6)**

33 (A-C) Analysis of the distribution of GFP::RAB-3 positive puncta. (A and B) The

1 number of misaccumulation to the commissure region (A) and the distance of dorsal
2 asynaptic region (B) were counted as Figure 1H. (C) The distribution of the interpunctal
3 distance in wild type (WT), *arl-8(wy271)* and *arl-8(wy874)*. In *arl-8(wy874)*, the
4 length of intersynapses is significantly longer compared to *arl-8(wy271)*. ($p < 0.01$,
5 Mann–Whitney *U* test , $n = 76$ intersynapses from 4 animals), but is significantly
6 shorter than wt ($p < 0.01$, Mann–Whitney *U* test , $n = 76$ intersynapses from 4
7 animals).

8 (D-F) Vesicle movement was analyzed as described in Figure 5. (D) Representative
9 kymographs from *arl-8(wy271)* and *arl-8(wy874)*. Scale bars, 6 sec and 5 μm ,
10 respectively. Anterograde events have negative slope, and retrograde events have
11 positive slope, from left to right. (E and F) Mean pause times per pause (E) and
12 Anterograde frequency (F) in each genotype. Kruskal-Wallis test *, $p < 0.1$, **, $p < 0.05$
13 and ***, $P < 0.01$, respectively.

14 (G-J) Rescue of *arl-8(wy271)* by different genomic fragments. Genomic DNA
15 amplified from indicated genotypes were injected into *arl-8(wy271)* animals.
16 Representative images of animals that carry (G) wt genomic DNA, (H) *arl-8(wy271)*
17 genomic DNA and (I) *arl-8(wy874)* genomic DNA. (J) Transgenic animals from two
18 independent transgenic lines were scored for rescue and plotted. *, $p < 0.01$, compared
19 to wt genomic injection, Chi-square test, $n = 50$ worms. Scale Bars, 50 μm .

20 (K) Subcellular localization of UNC-104(WT)::GFP in the presence of wt and mutant
21 forms of ARL-8 mutants. As a control, the result of UNC-104(V6I) is shown as well.
22 *, $p < 0.05$, Chi-square test with Bonferroni correction, $n = 100$ worms.

23 (L and M) ARL8B(Q75L), ARL8B(D133N) and ARL8B(T34N) were coexpressed with
24 KIF1A::GFP and GFP signals were detected. Confocal images (L) and Statistical
25 analysis (M). While The GDP mutant (T34N) did not activate KIF1A, the GTP mutants
26 (Q75L and D133N) strongly drive KIF1A onto microtubules and vesicles. $n = 30$ cell, *,
27 $p < 0.05$, Chi-square test with Bonferroni correction. Bars, 10 μm .

28 (N) Microtubule binding assay. KIF1A and ARL8B mutants were co-transfected to
29 COS cells and microtubule binding assay was performed as described in Figure 2F.
30 Note that the GTP mutants drive KIF1A to microtubule fraction.

31

32 **Figure S5 (related to Figure 7)**

33 In wild type, UNC-104 is in the inactive state by autoinhibition. GTP-ARL-8 on

1 synaptic vesicle precursors unlocks the autoinhibition of UNC-104. Activated UNC-104
2 can binds to both vesicles and microtubules.
3 In *arl-8(wy271)*, because of the promoter mutation (Fig. 7A), the amount of ARL-8 is
4 not enough to activate UNC-104. This causes the reduction of axonal transport.
5 In *arl-8(wy271); unc-104(gf)*, UNC-104 is in the active state. Thus, axonal transport is
6 sufficiently activated although the amount of ARL-8 is reduced.
7 In *arl-8(wy874)*, all the ARL-8 is in the GTP state. Then, UNC-104 can be sufficiently
8 activated although the expression level of ARL-8 is reduced.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

1 **Supplemental Experimental Procedure**

2 ***Worm genetics***

3 *C. elegans* was maintained on OP50 feeder as described in the standard protocol (Brenner, 1974). Strains
4 were maintained 20 °C and observed at room temperature except where otherwise noted.

5

6 ***Strains***

7 *wyIs85* [*Pitr-1::gfp::rab-3*, *Podr-1::dsred*], *arl-8(wy271)*; *wyIs85* and *unc-104(wy673)* were described
8 previously (Klassen and Shen, 2007; Klassen et al., 2010; Wu et al., 2013).

9

10 ***Genetic modifier screens of arl-8 mutant***

11 *arl-8(wy271)*; *wyIs85* L4 animals were treated with EMS as described (Wu et al., 2013). Worms were
12 maintained at 20 °C. F1 self progenies were screen under a 63X objective on an AxioPlan2 upright
13 microscope for GFP::RAB-3 distribution phenotypes that deviate from that of the starting strain.

14

15 ***Antibodies and plasmids***

16 *unc-104* cDNA was amplified by PCR and cloned into pSM GFP vector (a gracious gift of Steven
17 McCarroll and Cori Bargmann). Then the *itr-1* promoter is ligated to the upstream of *unc-104* cDNA. The
18 KIF1A::GFP vector and the anti-KIF1A antibody are described previously (Niwa et al., 2008). Anti-GFP
19 antibody (#598) was obtained from MBL (Nagoya, Japan). TUBB5::TagRFP is described previously
20 (Niwa et al., 2013). Anti-snb-1 antibody was described previously (Hadwiger et al., 2010).

21 To introduce gain-of-function mutations into *unc-104* and KIF1A vectors, PCR based mutagenesis was
22 performed using KOD-plus-high fidelity DNA polymerase (TOYOBO, Tokyo, Japan).

23

24 ***Microtubule binding assay***

25 293T cells (Life Technologies, Waltham, MA, USA) were maintained in DMEM medium (Life
26 Technologies) supplemented with 10% FBS (Life Technologies) in a CO2 incubator at 37 °C. One day
27 before the transfection, cells were transferred to ø10 cm dishes. Vectors encoding KIF1A::GFP and its
28 mutants were transfected by Lipofectamine 2000 (Life Technologies) as described in the manufacture's
29 protocol and incubated for 36 hours. Cells were lysed in PEM buffer (100 mM Pipes, 1mM EGTA and
30 1mM MgCl₂) supplemented with 0.1 % Triton-X100 and a complete mini proteinase inhibitor tablet
31 (Roche, Basel, Swiss). Debris was removed by ultracentrifuge using a TLA-55 rotor (Beckman Coulter,
32 Brea, CA, USA) at 45,000 rpm at 4 °C for 10 min. Lysate fractions were used as input fractions (In). 10
33 µM tubulin purified from porcine brains and 0.5 mM AMP-PNP were added and incubated for 10 min at

1 37 °C. Then, 20 µM taxol was added and incubated for another 10 min at 37 °C. Polymerized
2 microtubules (MT) and supernatant (S) fractions were separated by ultracentrifuge at 45000 rpm 27 °C
3 for 10 min. Each fraction was analyzed by western blot using the anti-GFP antibody.

4 5 ***GST pull down***

6 GST-fused ARL8B and ARL-8 mutants were expressed in BL21RIL (Agilent Technologies, Santa Clara,
7 CA, USA). Cells transformed with GST, GST-ARL8B, GST-ARL8B(T34N) and GST-ARL8B(Q75L)
8 vectors were cultured in 5 ml LB medium supplemented with 50 mg/ml ampicillin. Cells with the
9 GST-ARL8B(D133N) vector were cultured in 30 ml medium due to low expression level . Protein
10 expression was induced by 0.2 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and cultured for 16
11 hours at 18 °C. Cells were collected by a bench top centrifuge (Beckman) at 3000 g for 10 min at room
12 temperature and then lysed in B-PER reagent (Thermo Scientific, Waltham, MA, USA) at 4 °C. Lysate
13 was separated by centrifuge at 15000 rpm for 10 min at 4 °C. Into the lysate, 40 ul bed volume of
14 Glutathione sepharose 4B (GE Healthcare Life Science, Pittsburgh, PA, USA) was added and incubated
15 for 1 hour. After the incubation, beads were washed twice with immunoprecipitation buffer (10 mM Tris,
16 pH 7.4, 150 mM NaCl, 0.1 % Nonidet P40). Proteins were eluted by SDS-PAGE sample buffer (125 mM
17 Tris, pH 6.8, 4 % SDS, 20 % Glycerol, 0.01 % bromophenol blue) freshly supplemented with 10 %
18 volume of 2-mercaptoethanol (Sigma Aldrich) and boiled at 95 °C.

19 20 ***C. elegans transgenesis***

21 Injection was performed as described (Mello and Fire, 1995). Glass needles were prepared using a
22 MODEL P-2000 micropipette puller (Sutter Instrument, Novato, CA, USA). A FemtoJet microinjection
23 system (Eppendorf, Hamburg, Germany) was used for microinjection.

24 25 ***Confocal microscopy***

26 *wyIs85 [Pitr-1::gfp::rab-3; Podr-1::rfp]* was used as a synaptic vesicle marker in DA9 neuron. Animals
27 were fixed by 4 % Paraformaldehyde on the 5% agarose pad prepared as described. Images were taken
28 using an Axio Observer. Z1 microscope equipped with a LSM710 confocal system (Carl Zeiss) using
29 Plan-Apochromat (x63, N.A. 1.4) objective lens. Z stack images were saved as the lsm format, analyzed
30 and reconstituted using NIH image.

31 32 ***Computer-based Image analysis***

33 Computer-based image analysis was performed as described (Crane et al., 2012). In short, *C. elegans*

1 individuals are suspended in fluid, that pressure driven into the imaging chamber of a
2 polydimethylsiloxane (PDMS) soft microfluidic device. Pneumatic, automatically-controlled valves
3 temporarily confine individuals for epifluorescent imaging, discarding individuals that do not display
4 DA9 in the imaging region. A previously-trained support vector machine (SVM) algorithm is used to
5 identify synapses within the images obtained, and custom software extracts synaptic properties from the
6 synapses identified (Chung et al., 2008; Crane et al., 2010).

7 8 ***Live cell imaging***

9 Axonal transport was visualized using *wyIs251 [Pmig-13::gfp::rab-3; Pord-1::gfp]* as described. Worms
10 were anesthetized in M9 buffer supplemented with 2 mM Levamisole and mounted on 5% agarose pad on
11 a slide. Time-lapse imaging was performed on a spinning disk confocal microscope with a
12 Plan-Apochromat 100x/1.4 objective and a 1.6x intermediate lens. Images were taken at 4 frames per
13 second for 1 min. Movies were analyzed by NIH image.

14 15 ***arl-8 rescue***

16 The *arl-8* genomic fragments were amplified by polymerase chain reaction (PCR) using
17 5'-TAAGCGGCGAGAACCGACATGCGTG-3' and 5'-CGCCTTCAAGAAATACAGTACCCCAC-3'.
18 KOD-plus-DNA polymerase kit (TOYOBO, Tokyo, Japan) was used with a slight modification. For
19 efficient reaction, 0.5 μ l of Taq DNA polymerase (New England Biolabs, USA) was added to each 50 μ l
20 reactions.

21 22 ***Microtubule gliding assays***

23 Microtubule gliding assay was performed as described (Carter and Cross, 2001; Niwa et al., 2012). The
24 vector encoding the motor domain of UNC-104 was obtained from Addgene (Pierce et al., 1999).
25 Proteins were expressed in BL21RIL(DE3) and purified by TALON Ni²⁺ sepharose (Takara-Clontech,
26 Tokyo, Japan). The gliding assay was performed in the flow chamber, consisting of 24- x 40 -mm and 18-
27 x 18-mm glass coverslips (Matsunami, Tokyo, Japan), attached by double-sided tape (3M, Maplewood,
28 MN, USA). Purified motors were diluted in gliding assay buffer (80 mM Pipes, pH 6.9, 1mM EGTA,
29 1mM MgCl₂, 1 mM DTT, 10 mM taxol, 0.5 mg/ml casein) and fixed on the coverslip using
30 anti-penta-His antibody (Qiagen). TMR-labeled microtubules were flowed. ELYRA P.1 system (Carl
31 Zeiss) was used in the total internal fluorescent microscopy (TIRF) mode.

32 33 ***Visualization of KIF1A and microtubule in COS-7 cells***

1 Compared to unfixed cells (Figure 2B), KIF1A-GFP was detached in cells fixed by the 4%
2 paraformaldehyde or cold methanol. Thus, we coexpressed TUBB5-TagRFP in order to visualize
3 microtubules as described (Niwa et al., 2013). Cells were directly observed by spinning disc microscopy
4 as described above.

5 6 **Statistics**

7 Statistical methods and the sample size are described in each figure legends. t-test and Chi-square tests
8 and Bonferroni correction were performed using Excel (Microsoft Corporation, Redmond, WA, USA),
9 Mann–Whitney *U* test was performed using Excel Toukei (SSRI, Tokyo, Japan) and Kruskal-Wallis test
10 was performed using MATLAB (MathWorks, Natick, MA, USA).

11 12 13 14 **Supplementary References**

- 15 Brenner, S. (1974). The genetics of *Caenorhabditis elegans*. *Genetics* 77, 71-94.
- 16 Carter, N., and Cross, R. (2001). An improved microscope for bead and surface-based motility assays.
17 *Methods Mol Biol* 164, 73-89.
- 18 Chung, K., Crane, M.M., and Lu, H. (2008). Automated on-chip rapid microscopy, phenotyping and
19 sorting of *C. elegans*. *Nat Methods* 5, 637-643.
- 20 Crane, M.M., Chung, K., Stirman, J., and Lu, H. (2010). Microfluidics-enabled phenotyping, imaging,
21 and screening of multicellular organisms. *Lab Chip* 10, 1509-1517.
- 22 Crane, M.M., Stirman, J.N., Ou, C.Y., Kurshan, P.T., Rehg, J.M., Shen, K., and Lu, H. (2012).
23 Autonomous screening of *C. elegans* identifies genes implicated in synaptogenesis. *Nat Methods* 9,
24 977-980.
- 25 Hadwiger, G., Dour, S., Arur, S., Fox, P., and Nonet, M.L. (2010). A monoclonal antibody toolkit for *C.*
26 *elegans*. *PLoS One* 5, e10161.
- 27 Klassen, M.P., and Shen, K. (2007). Wnt signaling positions neuromuscular connectivity by inhibiting
28 synapse formation in *C. elegans*. *Cell* 130, 704-716.
- 29 Klassen, M.P., Wu, Y.E., Maeder, C.I., Nakae, I., Cueva, J.G., Lehrman, E.K., Tada, M., Gengyo-Ando,
30 K., Wang, G.J., Goodman, M., *et al.* (2010). An Arf-like small G protein, ARL-8, promotes the axonal
31 transport of presynaptic cargoes by suppressing vesicle aggregation. *Neuron* 66, 710-723.
- 32 Mello, C., and Fire, A. (1995). DNA transformation. *Methods Cell Biol* 48, 451-482.

- 1 Niwa, S., Nakajima, K., Miki, H., Minato, Y., Wang, D., and Hirokawa, N. (2012). KIF19A is a
2 microtubule-depolymerizing kinesin for ciliary length control. *Dev Cell* 23, 1167-1175.
- 3 Niwa, S., Takahashi, H., and Hirokawa, N. (2013). β -Tubulin mutations that cause severe neuropathies
4 disrupt axonal transport. *EMBO J* 32, 1352-1364.
- 5 Niwa, S., Tanaka, Y., and Hirokawa, N. (2008). KIF1B β - and KIF1A-mediated axonal transport of
6 presynaptic regulator Rab3 occurs in a GTP-dependent manner through DENN/MADD. *Nat Cell Biol* 10,
7 1269-1279.
- 8 Pierce, D.W., Hom-Booher, N., Otsuka, A.J., and Vale, R.D. (1999). Single-molecule behavior of
9 monomeric and heteromeric kinesins. *Biochemistry* 38, 5412-5421.
- 10 Wu, Y.E., Huo, L., Maeder, C.I., Feng, W., and Shen, K. (2013). The balance between capture and
11 dissociation of presynaptic proteins controls the spatial distribution of synapses. *Neuron* 78, 994-1011.
- 12